Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Completed · Phase 2

Conditions studied: Glioblastoma

In brief

This is an ongoing Phase 2, open-label, multicenter, non-randomized study of MEDI4736 (durvalumab) in subjects with glioblastoma (GBM) enrolled into 5 non-comparative cohorts. Primary study objectives, which vary by cohort due to differences in subject populations, include evaluation of the clinical efficacy as measured by the overall survival (OS) rate at 12 months (Cohort A), progression-free survival (PFS) at 6 months (Cohorts B, B2, and B3), and OS at 6 months (Cohort C). For all cohorts, secondary objectives include evaluation of the safety/tolerability and clinical efficacy of study treatment, and exploratory objectives include evaluation of the neurologic function and correlative biomarkers.

Key facts

Study ID

NCT02336165

Run by

Ludwig Institute for Cancer Research

People needed

159

Starts

2015-02-26

Expected to finish

2021-07-06

Last updated by the study team

2022-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Facility — Los Angeles, California, United States
• Research Facility — San Francisco, California, United States
• Research Facility — Baltimore, Maryland, United States
• Research Facility — Boston, Massachusetts, United States
• Research Facility — Boston, Massachusetts, United States
• Research Facility — St Louis, Missouri, United States
• Research Facility — New York, New York, United States
• Research Facility — Melbourne, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.